Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Giles

Showing results (571-580 of 610) with videos related to

Pageof 61
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 25, 2010
Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3Thomas Fischer, Richard M Stone, Daniel J Deangelo, et al.
Neuro-Oncology|January 3, 2018
Protein phosphatase 2A inhibition enhances radiation sensitivity and reduces tumor growth in chordomaShuyu Hao, Hua Song, Wei Zhang, et al.
Cancer|April 4, 2003
Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseasesFrancis J Giles, Maureen A Cooper, Lewis Silverman, et al.
Molecular Imaging and Biology|July 10, 2010
MicroCT-based virtual histology evaluation of preclinical medulloblastomaSuresh I Prajapati, Aoife Kilcoyne, Aislynn K Samano, et al.
Leukemia Research|August 19, 2003
Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemiaFrancis J Giles, Paula M Fracasso, Hagop M Kantarjian, et al.
Leukemia|March 12, 2021
Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trialJerald P Radich, Andreas Hochhaus, Tamás Masszi, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 25, 2009
Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generationAnnelie E Abrahamsson, Ifat Geron, Jason Gotlib, et al.
Journal of Cancer Research and Clinical Oncology|February 23, 2017
Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysisAndreas Hochhaus, Franҫois-Xavier Mahon, Philipp le Coutre, et al.
Leukemia|July 6, 2012
Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II studyF J Giles, P D le Coutre, J Pinilla-Ibarz, et al.
Leukemia|June 24, 2020
Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND studyAndreas Hochhaus, Carlo Gambacorti-Passerini, Camille Abboud, et al.
Pageof 61

Showing results (571-580 of 610) with videos related to

Sort By:
Pageof 61
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 25, 2010
Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3Thomas Fischer, Richard M Stone, Daniel J Deangelo, et al.
Neuro-Oncology|January 3, 2018
Protein phosphatase 2A inhibition enhances radiation sensitivity and reduces tumor growth in chordomaShuyu Hao, Hua Song, Wei Zhang, et al.
Cancer|April 4, 2003
Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseasesFrancis J Giles, Maureen A Cooper, Lewis Silverman, et al.
Molecular Imaging and Biology|July 10, 2010
MicroCT-based virtual histology evaluation of preclinical medulloblastomaSuresh I Prajapati, Aoife Kilcoyne, Aislynn K Samano, et al.
Leukemia Research|August 19, 2003
Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemiaFrancis J Giles, Paula M Fracasso, Hagop M Kantarjian, et al.
Leukemia|March 12, 2021
Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trialJerald P Radich, Andreas Hochhaus, Tamás Masszi, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 25, 2009
Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generationAnnelie E Abrahamsson, Ifat Geron, Jason Gotlib, et al.
Journal of Cancer Research and Clinical Oncology|February 23, 2017
Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysisAndreas Hochhaus, Franҫois-Xavier Mahon, Philipp le Coutre, et al.
Leukemia|July 6, 2012
Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II studyF J Giles, P D le Coutre, J Pinilla-Ibarz, et al.
Leukemia|June 24, 2020
Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND studyAndreas Hochhaus, Carlo Gambacorti-Passerini, Camille Abboud, et al.
Pageof 61